Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
Jennifer A. Chan(Dana-Farber Cancer Institute), Matthew H. Kulke(Moffitt Cancer Center), Rebecca A. Miksad(Brigham and Women's Hospital), Pankaj Bhargava(University of North Carolina at Chapel Hill), Hui Zheng(Association for Jewish Studies), Craig C. Earle(Canadian Partnership Against Cancer), Keith Stuart(Brigham and Women's Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Peter C. Enzinger(Dana-Farber Cancer Institute), Charles S. Fuchs(University of Southern California), Jeffrey A. Meyerhardt(CancerCare)
Cited by 301
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k